# About MD Semaglutide — editorial standards and scope > MD Semaglutide is an independent research-summary publisher covering the semaglutide clinical literature. Editorial standards, scope, and disclaimers. MD Semaglutide is an independent editorial summary of the semaglutide research literature. Not a clinic. Not a pharmacy. Not affiliated with any vendor. ## What this site is MD Semaglutide is a research-summary publication. The goal is to translate the peer-reviewed semaglutide literature — the SUSTAIN, STEP, SELECT, FLOW, PIONEER, and ESSENCE Phase 3 programs, plus the relevant pharmacology, safety, and mechanism reviews — into plain English for clinicians, journalists, students, and prospective patients who want a structured view of the evidence base. It is not a clinical practice. It does not provide individualized medical advice. The `md` in the domain name reflects the editorial emphasis: who studies this molecule, what board certifications and training matter when a clinician is prescribing it, and how the trial program has been organized across specialties (endocrinology, obesity medicine, cardiology, nephrology, hepatology). The site does not promote any specific provider, clinic, or brand. ## Editorial standards Every quantitative claim on this site cites a specific study from the primary literature. Trial names, populations, doses, durations, primary outcomes, hazard ratios, and confidence intervals come directly from the published reports — not from press releases, marketing materials, or downstream summaries. Where the literature is preliminary (for example, the Phase 2 alcohol-use-disorder data), the page makes that explicit. We do not use brand names. Semaglutide is referred to throughout by its International Nonproprietary Name. Other GLP-1 receptor agonists are similarly named generically (liraglutide, dulaglutide, exenatide). This is an editorial choice: the science is about the molecule, not the trade dress. We do not give medical advice. Pages describing dosing schedules summarize what the FDA prescribing information and pivotal trials describe; they do not recommend that any specific reader take any specific dose. A licensed prescriber, evaluating an individual patient, makes those decisions. We do not link to other sites in our portfolio in the body of any page. We do not run advertising. We do not sell anything. ## Scope and limitations The site covers semaglutide specifically — not the GLP-1 receptor agonist class as a whole, not the broader obesity-pharmacotherapy landscape, and not the dual-agonist (GLP-1/GIP) successors. Comparisons with other agents are limited to head-to-head trials where semaglutide was the index drug (for example, SUSTAIN 7 vs dulaglutide [6] and STEP 8 vs liraglutide [7]). The research summarized here is current as of the publication dates of the cited studies. Clinical practice and labeling change. Readers should consult the current FDA prescribing information and their healthcare provider for decisions that affect their care. ## Disclaimer Editorial commentary on published research and FDA-approved prescribing information. Not medical advice. Consult a qualified healthcare provider for any clinical question. MD Semaglutide is not affiliated with any vendor or manufacturer and does not offer clinical services. --- An independent summary of published clinical-trial evidence — not medical advice, not a clinic, not a prescription.